RAY THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2021-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
Phase 1
Recruiting
- Conditions
- Retinitis PigmentosaChoroideremia
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Ray Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT06460844
- Locations
- 🇺🇸
UPMC Vision Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸UCI Alpha Clinic, Orange, California, United States
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
Recruiting
- Conditions
- Retinitis PigmentosaChoroideremiaStargardt Macular DystrophyStargardt DiseaseGeographic Atrophy from Age-related Macular DegenerationX-lined RetinoschisisRetinal Dystrophies
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Ray Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06375239
- Locations
- 🇺🇸
Vision Research and Assessment Institute, Irvine, California, United States
News
No news found